Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirukumab long-term extension in rheumatoid arthritis
NL-OMON40162Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of sirukumab in rheumatoid arthritis (RA) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Long-term safety of sirukumab. Started Jul 2014; status: active, not recruiting.
02
Drugs
sirukumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON40162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40162.